About Immunoglobulin heavy constant alpha 2
Immunoglobulin heavy constant alpha 2 (IGHA2) is a protein
from Homo sapiens identified by UniProt accession
P01877, 391 residues long.
MolForge cross-references it against 0 known binders and
229 disease associations.
Target properties
| Protein name | Immunoglobulin heavy constant alpha 2 |
| UniProt accession | P01877 |
| Gene | IGHA2 |
| Organism | Homo sapiens |
| Length | 391 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | LOW |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (229)
Diseases linked to this target (Open Targets).
- isolated agammaglobulinemia · score 0.08
- immunodeficiency 35 · score 0.07
- common variable immunodeficiency · score 0.07
- Chronic mucocutaneous candidosis · score 0.07
- varicella, severe recurrent · score 0.07
- severe combined immunodeficiency due to CARD11 deficiency · score 0.07
- severe combined immunodeficiency due to CTPS1 deficiency · score 0.07
- candidiasis, familial, 4 · score 0.07
- hyper-IgM syndrome type 3 · score 0.07
- ICF syndrome · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P01877-F1 | alphafold | PREDICTED | 82.98 | — |
Amino-acid sequence (391 residues)
ASPTSPKVFP LSLDSTPQDG NVVVACLVQG FFPQEPLSVT WSESGQNVTA RNFPPSQDAS GDLYTTSSQL TLPATQCPDG KSVTCHVKHY TNSSQDVTVP CRVPPPPPCC HPRLSLHRPA LEDLLLGSEA NLTCTLTGLR DASGATFTWT PSSGKSAVQG PPERDLCGCY SVSSVLPGCA QPWNHGETFT CTAAHPELKT PLTANITKSG NTFRPEVHLL PPPSEELALN ELVTLTCLAR GFSPKDVLVR WLQGSQELPR EKYLTWASRQ EPSQGTTTYA VTSILRVAAE DWKKGETFSC MVGHEALPLA FTQKTIDRMA GSCCVADWQM PPPYVVLDLP QETLEEETPG ANLWPTTITF LTLFLLSLFY STALTVTSVR GPSGKREGPQ Y
Explore Immunoglobulin heavy constant alpha 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets